scispace - formally typeset
E

Elizabeth M. Swisher

Researcher at University of Washington

Publications -  289
Citations -  24067

Elizabeth M. Swisher is an academic researcher from University of Washington. The author has contributed to research in topics: Ovarian cancer & PARP inhibitor. The author has an hindex of 69, co-authored 253 publications receiving 18684 citations. Previous affiliations of Elizabeth M. Swisher include University of Washington Medical Center & Fred Hutchinson Cancer Research Center.

Papers
More filters
Journal ArticleDOI

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

Katherine A Hoadley, +738 more
- 05 Apr 2018 - 
TL;DR: Molecular similarities among histologically or anatomically related cancer types provide a basis for focused pan-cancer analyses, such as pan-gastrointestinal, Pan-gynecological, pan-kidney, and pan-squamous cancers, and those related by stemness features, which may inform strategies for future therapeutic development.
Journal ArticleDOI

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, +116 more
- 28 Oct 2017 - 
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI

Secondary mutations as a mechanism of cisplatin resistance in BRCA2 -mutated cancers

Wataru Sakai, +11 more
- 28 Feb 2008 - 
TL;DR: The results suggest that secondary mutations that restore the wild-type BRCA2 reading frame may be a major clinical mediator of acquired resistance to platinum-based chemotherapy.
Journal ArticleDOI

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Elizabeth M. Swisher, +30 more
- 01 Jan 2017 - 
TL;DR: The ability of tumour genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor, was assessed in ARIEL2, an international, multicentre, two-part, phase 2, open-label study.
Journal ArticleDOI

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

Tom Walsh, +14 more
- 01 Nov 2011 - 
TL;DR: Using targeted capture and massively parallel genomic sequencing, this paper screened for germ-line mutations in 21 tumor suppressor genes in genomic DNA from women with primary ovarian, peritoneal, or fallopian tube carcinoma.